Astellas is already a proven player in the fields of Transplantation, Urology,Anti-Infectives and Pain Management – a position we have achieved through a commitment to innovation. We are now bringing this expertise to bear in the field of oncology.

With a strong commitment to research and development, we are dedicated to building a strong presence in this most challenging of therapeutic areas where a high level of unmet medical need exists.

Our mission is, to play a key role in the advancement of oncology treatments, with a positive look to the future. Astellas Pharma is committed to making every endeavour to provide products that are recognised worldwide as improving outcomes for patients in every way possible following diagnosis of metastatic castration resistance prostate cancer mCRPC.

CRPC is an advanced stage prostate cancer when the disease shows signs of progression despite castration levels of testosterone. Patients with castration-resistant disease in whom cancer cells have metastasised from the prostate to other parts of the body, most notably the bones and lymph nodes are said to have mCRPC, and it is the presence of metastatic disease which is often associated with symptoms.1

In the early stages, prostate cancer is localised to the prostate and driven by androgens. At this stage, the disease may be treated with surgery or radiotherapy, or depending on the risk/benefit conservative management may be adopted (watchful waiting/active surveillance). Patients who have inoperable locally advanced or metastatic disease at diagnosis or who have inoperable recurrent disease are treated with ADT as the disease is usually ‘hormone sensitive’ at this stage.

As the disease progresses, the tumour ceases to respond to androgen deprivation and becomes castration-resistant. CRPC tumours are not sensitive to ADT but may respond to therapy with anti-androgens (or anti-androgen withdrawal), inhibitors of androgen production, and estrogenic agents that further inhibit luteinising hormone. However, the rate of response to these treatments is limited.

Prostate cancer incidence is strongly related to age, with the highest incidence rates being in older men. In 2011, median age at prostate cancer diagnosis in Ireland was 67 years with 38.9% of cases being diagnosed in men 65 to 74 years of age and 21.3% in men 75+ years.1 Median age at death was 80 with 70.3% of deaths occurring in men 75+ years.

Source: National Cancer Registry Ireland.1

It is well known that the progression of prostate cancer to mCRPC is an incredibly difficult transition emotionally for patients. However, what matters most to patients at this time is to be able to continue living their lives with minimal disruption –keeping prostate cancer in the back ground, with an ongoing sense of free will to live the way they want.

As a leading pharmaceutical company, Astellas Pharma is committed to provided medicines for mCRPC both before & after chemotherapy. Astellas Pharma is committed to making every endeavour to provide products that improve outcomes for patients in every way possible following a diagnosis of mCRPC.